34 research outputs found

    Economic evaluation of prematurity : a first year of life with major issues : the case of France

    No full text
    Cette thèse présente la première évaluation économique de la prématurité en France. La prématurité intervient avant 37 semaines d’aménorrhée. Elle est en constante augmentation dans le monde. Si les enjeux de santé publique sont bien identifiés, la prise en charge et les choix collectifs en matière de prématurité comportent des enjeux économiques importants. La première partie de cette thèse présente les enjeux de santé publique de la prématurité et les efforts restant à fournir en matière de prévention en France. Elle conduit ensuite une réflexion économique sur les moyens d’une utilisation au plus « juste » socialement des ressources dédiées à la santé périnatale, dans le contexte d’augmentation des dépenses de santé. Une mesure de la charge collective de la prise en charge de la prématurité est nécessaire et envisagée au moyen d’une étude Cost-Of-Illness. Enfin elle pose le cadre dans lequel l’éthique et l’évaluation économique sont complémentaires. La deuxième partie présente la méthodologie et les résultats de l’étude, consistant à évaluer les coûts directs hospitaliers et extrahospitaliers des naissances prématurées et à terme, dans la première année de vie, du point de vue de l’Assurance Maladie. Les données sont extraites du Système National d’Information Inter-Régime de l’Assurance Maladie. Les résultats montrent l’ampleur des coûts moyens associés à la grande prématurité et une relation inverse et significative entre les coûts moyens et l’âge gestationnel. Cette étude économique invite à la sensibilisation des décideurs publics à la nécessité d’allouer les moyens financiers et humains pour prévenir la survenue de situations critiques associées à la prématurité.This thesis focuses on a first economic assessment of prematurity in France. Prematurity is defined as occurring before 37 weeks of gestation. It is increasing in France and worldwide. If the issues of public health are already well identified, medical care and collective choices concerning prematurity matters also involve significant economic challenges. The first part of this thesis attempts to present the public health issues of prematurity and highlights the remaining efforts required to provide prevention in France. It then considers economic issues on the use of socially fairer resources dedicated to perinatal health in a context where current health expenditure is rising. Assessment of the collective burden of care for preterm infants is necessary and envisaged by a Cost-Of-Illness study. Finally it presents a framework where ethical and economic considerations are complementary. The second part addresses the methodology and results of the study. The study assesses the hospital and non-hospital direct costs for preterm and term births, in the first year of life, from health insurance point of view. It is based on an extraction of data from the National Heal Insurance Inter-Regime Information System. The results of the study highlight in particular the level of average costs associated with extreme prematurity (before 32 weeks) and demonstrate an inverse and significant relationship between average costs and the gestational age (GA) at birth. This economic study invites awareness of the policy makers about the need to provide financial and human resources to anticipate and prevent critical situations associated with prematurity

    Evaluation économique de la prématurité : une première année de vie aux enjeux majeurs : le cas de la France

    No full text
    This thesis focuses on a first economic assessment of prematurity in France. Prematurity is defined as occurring before 37 weeks of gestation. It is increasing in France and worldwide. If the issues of public health are already well identified, medical care and collective choices concerning prematurity matters also involve significant economic challenges. The first part of this thesis attempts to present the public health issues of prematurity and highlights the remaining efforts required to provide prevention in France. It then considers economic issues on the use of socially fairer resources dedicated to perinatal health in a context where current health expenditure is rising. Assessment of the collective burden of care for preterm infants is necessary and envisaged by a Cost-Of-Illness study. Finally it presents a framework where ethical and economic considerations are complementary. The second part addresses the methodology and results of the study. The study assesses the hospital and non-hospital direct costs for preterm and term births, in the first year of life, from health insurance point of view. It is based on an extraction of data from the National Heal Insurance Inter-Regime Information System. The results of the study highlight in particular the level of average costs associated with extreme prematurity (before 32 weeks) and demonstrate an inverse and significant relationship between average costs and the gestational age (GA) at birth. This economic study invites awareness of the policy makers about the need to provide financial and human resources to anticipate and prevent critical situations associated with prematurity.Cette thèse présente la première évaluation économique de la prématurité en France. La prématurité intervient avant 37 semaines d’aménorrhée. Elle est en constante augmentation dans le monde. Si les enjeux de santé publique sont bien identifiés, la prise en charge et les choix collectifs en matière de prématurité comportent des enjeux économiques importants. La première partie de cette thèse présente les enjeux de santé publique de la prématurité et les efforts restant à fournir en matière de prévention en France. Elle conduit ensuite une réflexion économique sur les moyens d’une utilisation au plus « juste » socialement des ressources dédiées à la santé périnatale, dans le contexte d’augmentation des dépenses de santé. Une mesure de la charge collective de la prise en charge de la prématurité est nécessaire et envisagée au moyen d’une étude Cost-Of-Illness. Enfin elle pose le cadre dans lequel l’éthique et l’évaluation économique sont complémentaires. La deuxième partie présente la méthodologie et les résultats de l’étude, consistant à évaluer les coûts directs hospitaliers et extrahospitaliers des naissances prématurées et à terme, dans la première année de vie, du point de vue de l’Assurance Maladie. Les données sont extraites du Système National d’Information Inter-Régime de l’Assurance Maladie. Les résultats montrent l’ampleur des coûts moyens associés à la grande prématurité et une relation inverse et significative entre les coûts moyens et l’âge gestationnel. Cette étude économique invite à la sensibilisation des décideurs publics à la nécessité d’allouer les moyens financiers et humains pour prévenir la survenue de situations critiques associées à la prématurité

    Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study.

    No full text
    Breast cancer (BC) screening has been developed to detect earlier stage tumors associated with better prognosis. The aim of study was to evaluate the impact of BC screening on therapeutic management of patients with first operable BC, and on costs, patients' needs, and working life. OPTISOINS01 was a multicenter, prospective observational study which aimed to identify the main care pathway of early BC. Among patients aged from 50 to 74 years-old, 2 groups were defined: the "Clinical signs" group and the "Screening" group (national organized screening and individual screening). We compared between these 2 groups: locoregional and systemic treatments, direct medical and non-medical costs from a National Health Insurance perspective, patients' needs assessed by the validated SCNS-BR8 "breast cancer" module of the SCNS-SF34 supportive care needs survey and the duration of sick leave. The "Clinical signs" group included 89 patients, while the"Screening" group included 290 patients. More axillary lymph node dissections and radical breast surgery were performed in the "Clinical signs". The rate of adjuvant chemotherapy was dramatically higher in the "Clinical signs" group. The median direct medical costs of the "Screening" group were €11,860 (€3,643-€41,030) per year and per patient, much lower than in the "Clinical signs" group (€14,940; €5,317-€41,070). Finally, needs specifically assessed by the SCNS-BR8 questionnaire were significantly higher for the postoperative and post-adjuvant periods in the "Clinical signs" group. This study highlighted the benefit of BC screening in terms of reduced therapies and positive impact on work and social life

    Paediatric intensive care admissions for respiratory syncytial virus bronchiolitis in France: results of a retrospective survey and evaluation of the validity of a medical information system programme

    No full text
    International audienceThe purpose of this study was to describe the characteristics of patients with bronchiolitis admitted to a paediatric intensive care unit (PICU), and to evaluate a national registry of hospitalizations (Programme de Médicalisation des Systèmes d'Information; PMSI) as a potential source of epidemiological data. Of the 49 French PICUs invited to take part in a retrospective survey of children aged \textless2 years who were hospitalized during the 2005-2006 epidemic season, 24 agreed to participate. Overall, 467 children were enrolled: 75% were aged \textless2 months, 76% had positive respiratory syncytial virus (RSV) tests, 34·9% required non-invasive ventilation, 36·6% were mechanically ventilated, and six infants died. The main neonatal characteristics were: prematurity (31·9%), respiratory disease (16·5%), congenital heart disease (6·4%), receiving mechanical ventilation (11·6%), and bronchopulmonary dysplasia at day 28 (3·8%). For bronchiolitis episode, the kappa coefficient between the survey and PMSI data was good only for mechanical ventilation (0·63) and the death rate (0·86)
    corecore